Natural Alternatives International, Inc. — FY2012 Form 10-K
Reporting period: Fiscal year ended June 30, 2012, compared with fiscal 2011. The filing is an annual report, not a report for calendar 2011 Q4.
Business context
NAI formulates and manufactures private-label nutritional supplements, licenses patent and trademark rights related to beta-alanine (CarnoSyn), and sells its own Pathway to Healing branded products. Private-label manufacturing remains the core business; operations include U.S. and Swiss facilities.
Financial performance and position
| Metric | FY2012 | FY2011 |
|---|---|---|
| Net sales | $72.8 million | $55.9 million |
| Gross profit / margin | $15.5 million / 21% | $10.6 million / 19% |
| Operating income / margin | $6.2 million / 9% | $2.3 million / 4% |
| Net income | $4.2 million | $5.1 million |
| Diluted EPS | $0.59 | $0.71 |
| Operating cash flow | $1.7 million | $9.1 million |
- Sales increased 30.3%. Private-label manufacturing sales rose 20.9% to $63.3 million; patent and trademark licensing sales reached $8.0 million, up from $1.7 million; branded product sales declined 14.3% to $1.6 million.
- Gross margin improved about 2.2 percentage points. Operating income rose 167%, while net income declined 18% as FY2011 included a $3.34 million tax benefit from reducing the deferred-tax valuation allowance. FY2012’s effective tax rate was 33.4%.
- Operating cash flow fell to $1.7 million, notably reflecting a $5.5 million use of cash from receivables and a $1.9 million use from inventory. Capital expenditures were $2.3 million.
- At June 30, 2012, cash and equivalents were $14.5 million, current assets $34.5 million, current liabilities $6.8 million, and total liabilities $7.3 million. NAI reported no outstanding debt and $5.5 million available under its credit facilities.
- Total assets were $47.2 million and stockholders’ equity $39.9 million. The company repurchased 75,026 shares for $405,000 during FY2012.
Material changes and management commentary
- The two largest manufacturing customers accounted for 63% of total sales, down from 73% in FY2011. NSA represented 44% and Mannatech 19% of FY2012 sales. Management aims to diversify customers and expects concentration to decline in FY2013.
- CarnoSyn-related revenue grew substantially, supported by licensing, royalties, and $3.4 million of beta-alanine raw-material sales. NAI says it does not expect material direct raw-material purchases and sales in FY2013.
- The filing’s detailed FY2012 segment discussion reports $4.0 million of royalty income, $654,000 of license fees, and $3.4 million of raw-material sales. Another overview describes $4.6 million of royalty and licensing revenue; investors should reconcile these descriptions with the reported $8.0 million segment total.
- Cash declined by $1.0 million during the year, despite positive operating cash flow, as investing and financing activities used cash. The company believes available cash and expected operating cash flows will cover working capital and capital expenditures for at least 12 months.
Outlook, risks, and unusual items
- Management anticipated positive net income in FY2013 and expected licensing and related revenue to expand, but provided no quantified earnings or revenue guidance. Planned priorities include growing manufacturing relationships, commercializing beta-alanine rights, developing Pathway to Healing, and improving efficiency.
- Management expected raw-material sourcing difficulties and pricing pressure to continue in FY2013, due to shortages and higher labor and transportation costs. The main beta-alanine supply factory in Japan had previously been disrupted by the 2011 earthquake; it resumed production, but future interruptions remain possible.
- Intellectual-property litigation and patent-compliance expenses were approximately $1.8 million in FY2012; management expected FY2013 litigation expenses of approximately $1.0–$1.5 million. Patent validity and infringement disputes could materially affect the licensing business. USPTO reexaminations of patents were accepted in July and August 2012.
- The Abbott beta-alanine agreement included contingent future fees, annual payments and potential royalties, but Abbott could terminate through October 31, 2012. A $354,167 payment due July 31, 2012 was received July 12; further payments and royalties were not assured. The Nestle agreement expired August 16, 2012 and was not renewed.
- Other significant risks include customer concentration and order timing, competition, regulatory compliance, product liability, supplier dependence, currency exposure, and the ability to protect intellectual property. The $5 million Wells Fargo credit line expires November 1, 2013 and is subject to covenants.
- NAI had $13.1 million in foreign-exchange contracts outstanding at year-end. A $784,000 net gain was recorded in other comprehensive income, with $741,000 of gross gain expected to be reclassified into earnings over the next 12 months alongside the related transactions.
Key facts investors should verify
- Whether operating cash generation improves, given the significant receivables and inventory cash uses in FY2012.
- Progress in reducing dependence on NSA and Mannatech, including customer contract renewals and order trends.
- FY2013 CarnoSyn royalties and licensing after the Nestle agreement’s expiration, Abbott’s termination window, and continuing patent litigation and reexaminations.
- Whether raw-material availability and cost inflation pressure manufacturing margins, and whether Pathway to Healing sales recover.
- Reconciliation of the filing’s different descriptions of CarnoSyn royalty and licensing revenue, and the timing and accounting effects of hedge gains.